| Revenue growth | 9% YoY for Q4 FY26; FY26 flat at ₹1798 Cr. |
|---|---|
| Margins | EBITDA margins impacted by new facility ramp-up costs and energy inflation. |
| Demand visibility | Strong CDMO pipeline; 54 active projects with 35 in commercial stage. |
| Management confidence | High for long-term CDMO growth and Atali phase 1 ramp-up. |
Growth
FY26 revenue hit ₹1798 Cr; EBITDA at ₹406 Cr. CDMO segment grew 32% YoY.
Outlook
Guiding 15-18% revenue/EBITDA growth for next 3-4 years. CDMO projected to grow 40-50% in FY27.
Risks
Geopolitical tensions in West Asia affecting logistics/energy costs; pricing pressure in API intermediates.
Earnings Call filed with BSE, NSE: AARTIPHARM. Summary written with AI assistance from the document.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹939.55
- Market cap
- ₹8,520 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 40.0×Sector 50.4×
- Promoter holding
- 42.86%-0.22% QoQ
- FII holding
- 8.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Promoter Selling: ₹106.4 Cr
Promoters sold a total of 15.12 lakh shares via open market transactions, aggregating to ₹106.43 Crore.
- Value
- ₹106.4 Cr
Aarti Pharmalabs Management Change
Aarti Pharmalabs reported directorate changes, including Shri Rashesh Gogri's appointment as Managing Director, Smt. Hetal Gogri Gala's re-designation, and the cessation of Shri Rajendra Gogri.
Aarti Pharmalabs Promoter Selling
Aarti Pharmalabs promoters sold a net 29.03 lakh shares, reducing their stake from 42.88% to 39.66%. No transaction value is disclosed in this periodic SAST filing.
Aarti Pharmalabs Investor Presentation: Key Takeaways
7th AGM presentation for Aarti Pharmalabs. Reported Standalone FY26 Revenue of INR 1,798 Cr with 23% EBITDA margin; Consolidated revenue down 14% YoY to INR 1,819 Cr.
- Call
- Guides 18% growth
Aarti Pharmalabs Annual General Meeting
Aarti Pharmalabs conducted its 7th Annual General Meeting on September 22, 2026, to transact ordinary and special business, with voting results to follow.
Aarti Pharmalabs Promoter Selling: ₹10.43 Cr
Promoter Group entities, Safechem Enterprises and Relacion Trusteeship, sold 1,19,400 shares of Aarti Pharmalabs in the open market for a total of ₹10.43 Crore.
- Value
- ₹10.43 Cr